David Haex

For the past twenty years, David has been supporting biotech, medtech and pharmaceutical companies in Belgium on their M&A and financing transactions as they search for innovation and growth opportunities. During this time, he has seen his clients grow from initial venture capital backed start-ups into Euronext-listed companies and even Nasdaq successes.

With almost 20 years of extensive sector experience, David specialises in every aspect of corporate transactional work, such as public and private M&As, venture capital transactions, general corporate lending, public offerings and general company law.

He has been consistently recommended in the legal directories for corporate M&A, where the corporate team is described as “without hesitation: excellent” and David himself being noted for “excelling at creating efficient solutions to complex problems”.

David and his team work with some of the biggest pharma and biotech companies and investors in the market. These include Bone Therapeutics, TiGenix, Gilde Healthcare, Takeda Ventures, Acutus Medical, Nevro and Novo Nordisk. Recent work highlights include advising TiGenix on its NASDAQ IPO and subsequent €520 million sale to Takeda, advising Bone Therapeutics on its €10 million PIPE with European and U.S. investors and advising Gilde Healthcare on its successful investment in Nyxoah.

David joined Osborne Clarke as a Partner in 2013. He obtained his law degree from the KU Leuven (2001) and an LL.M at King’s College London (2003). In January 2021, David took over as Managing Partner of the Brussels office where he continues to head the Corporate practice.

David is a regular speaker at national and regional events in Belgium, including the annual life sciences conference ‘Knowledge for Growth’, organised by flanders.bio which hosts over 1,000 attendees each year.

He also regularly contributes articles and commentaries on company law to the leading Belgian legal journal Revue de Droit Commercial Belge/Tijdschrift voor Belgisch Handelsrecht.